Evidence map›Paper›PMID 36016116›Full record

ArticleVaccines2022

Attitudes towards Vaccines, Intent to Vaccinate and the Relationship with COVID-19 Vaccination Rates in Individuals with Schizophrenia.

Stéphane Raffard, Sophie Bayard, Margot Eisenblaetter, Jérôme Attal, Christelle Andrieu, Isabelle Chereau, Guillaume Fond, Sylvain Leignier, Jasmina Mallet, Philippe Tattard and 4 more

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. The Australian and New Zealand journal of psychiatry · 2026
    Guideline
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Stéphane RaffardLaboratory EPSYLON, Paul Valéry University Montpellier 3, CEDEX 5, 34199 Montpellier, France.ORCID 0000-0001-5563-0323
Sophie BayardLaboratory EPSYLON, Paul Valéry University Montpellier 3, CEDEX 5, 34199 Montpellier, France.
Margot EisenblaetterLaboratory EPSYLON, Paul Valéry University Montpellier 3, CEDEX 5, 34199 Montpellier, France.
Jérôme AttalUniversity Department of Adult Psychiatry, CHU Montpellier, 34000 Montpellier, France.
Christelle AndrieuPôle Psychiatrie, Centre Expert Dépression Résistante et Schizophrénie Fonda Mental, CHU La Conception, 13005 Marseille, France.
Isabelle ChereauCHU Clermont-Ferrand, Service de Psychiatrie B, Université Clermont Auvergne, 63000 Clermont-Ferrand, France.
Guillaume FondPôle Psychiatrie, Centre Expert Dépression Résistante et Schizophrénie Fonda Mental, CHU La Conception, 13005 Marseille, France.
Sylvain LeignierCentre Référent de Réhabilitation Psychosociale et de Remeédiation Cognitive (C3R), CH Alpes Iseère, 38400 Saint-Martin-d'Hères, France.
Jasmina MalletAP-HP, Department of Psychiatry, Louis Mourier Hospital, 92700 Colombes, France.
Philippe TattardUniversity Department of Adult Psychiatry, CHU Montpellier, 34000 Montpellier, France.
Mathieu UrbachDepartment of Adult Psychiatry and Addictology, Versailles Hospital, Centre Hospitalier de Versailles, 177 rue de Versailles, 78157 Le Chesnay, France.
David MisdrahiDepartment of Adult Psychiatry, Charles Perrens Hospital, University of Bordeaux, Laboratory of Nutrition and Integrative Neurobiology (UMR INRA 1286), 33000 Bordeau, France.
Yasmine LarakiLaboratory EPSYLON, Paul Valéry University Montpellier 3, CEDEX 5, 34199 Montpellier, France.
Delphine CapdevielleUniversity Department of Adult Psychiatry, CHU Montpellier, 34000 Montpellier, France.
Université Paul-Valéry Montpellier · FRAix-Marseille Université · FRCentre Hospitalier Universitaire de Montpellier · FRInserm · FRCentre National de la Recherche Scientifique · FRUniversité Clermont Auvergne · FRUniversité de Bordeaux · FR

Funding

Agence Nationale de la Recherche SCHIZOVAC; ANR-21-COVR-0017
6 · The paper itself

Abstract

Schizophrenia patients are at high risk of developing severe COVID-19 outcomes but recent evidence suggests that they are under-vaccinated. This study explored the role of potential attitudinal barriers by comparing schizophrenia patients with participants from the general population regarding COVID-19 vaccination rates, general attitudes towards vaccines, and willingness to take a COVID-19 vaccine. We conducted a cross-sectional study between April 2021 and October 2021. A total of 100 people with schizophrenia and 72 nonclinical controls were recruited. In our study, individuals with schizophrenia were under-vaccinated, despite similar general attitudes towards vaccination and higher willingness to be vaccinated against COVID-19 compared to nonclinical participants. In patients, negative attitudes toward vaccines were related to higher levels of negative psychotic symptoms and higher levels of paranoid ideation. As a whole, participants with more negative attitudes towards vaccines were less likely to be vaccinated against COVID-19 and had lower levels of trust in institutions. Vaccine hesitancy does not appear to be a major barrier for COVID-19 vaccine uptake amongst people with schizophrenia. This study suggests that disparities in COVID-19 vaccination rates in schizophrenia do not seem related to attitudinal but rather structural barriers.

Indexed as

attitudesCOVID-19schizophreniavaccination

Identifiers

PMID36016116
PMCPMC9414756
OpenAlexW4289529002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.